Introduction {#s1}
============

The immune system employs several suppressive molecules and pathways to maintain T lymphocyte cell tolerance and prevent autoimmunity ([@B13]). Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), a coinhibitory molecule, is expressed on stimulated CD4^+^/CD8^+^ T cells to attenuate T cell activation. Of note, CTLA-4 also constitutively resides on Foxp3^+^ regulatory CD4^+^ T cells and directly facilitates the inhibitory function of regulatory T cells ([@B92]; [@B127]). Moreover, the programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway plays a predominant role in regulating T-cell-driven immune response. PD-1 exists inherently on the surface of T cells and is expressed on antigen-presenting cells (APCs), such as on macrophages and dendritic cells. The binding of these two molecules (PD1/PD/L1) can inhibit the immune response by reducing cytokine production and suppressing T-cell proliferation ([@B114]). Intriguingly, numerous cancer cells overexpress PD-L1 on their surface, which contributes to their immune evasion by enhancing immune escape ability, resulting in a poor prognosis ([@B45]).

Based on the inhibitory roles of these checkpoint molecules or pathways, several immune checkpoint inhibitors (ICIs), including PD-1 inhibitors (nivolumab and pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab, and durvalumab), and CTLA-4 inhibitors (ipilimumab and tremelimumab) have been developed to restore the T cell-mediated immune response and improve the efficacy of anti-tumor treatments ([@B133]; [@B102]). Encouragingly, these agents have revolutionized the treatment of various hematological and solid tumors ([@B97]; [@B124]; [@B94]).

The combination of ICIs, either use of multiple ICIs or ICIs combined with other therapies, such as chemotherapy, radiation, and anti-angiogenic drugs, has been associated with a significantly better prognosis than monotherapy ([@B65]). However, these reagents, both alone and in combination, also produce a wide spectrum of immune-related adverse events (irAEs), mainly due to aberrant autoreactive T cell activation ([@B131]; [@B87]; [@B96]). Immune-mediated toxicities can affect any organ or tissue involving the skin, gastrointestinal system, endocrine system, lung, or liver ([@B19]; [@B81]) and can largely be controlled by glucocorticoid therapy ([@B31]). Among these toxicities, cardiotoxicity, a potentially fatal irAE, has rarely been reported in early clinical trials of ICI therapy because of its low incidence and nonspecific symptomatology ([@B75]). Over the years, although increasing cases and case series of ICI-associated cardiotoxicity have been reported, it has not been fully recognized ([@B125]). Herein, to strengthen understanding of cardiotoxicity induced by ICIs and reduce deaths, we elaborate on the incidence, clinical manifestations, diagnosis, mechanisms, and outcomes of cardiotoxicity associated with ICIs. We will also discuss prophylactic strategies, potential treatments, and management of ICI-associated cardiotoxicity based on relevant literatures and current knowledge.

Incidence and Clinical Manifestations of Immune Checkpoint Inhibitor-Associated Cardiotoxicity {#s2}
==============================================================================================

Since the first specific case of ICI-associated cardiotoxicity was reported in 2014 ([@B43]), cardiotoxicity during ICI treatment has been reported in a gradually increasing number of patients ([@B36]; [@B67]; [@B44]; [@B54]; [@B63]; [@B115]; [@B11]; [@B88]; [@B101]; [@B117]). Cardiotoxicity attributed to ICIs spreads to almost all parts of the heart ([**Figure 1**](#f1){ref-type="fig"}) and involves both inflammatory cardiotoxicity and non-inflammation-mediated cardiotoxicity. The former includes myocarditis, perimyocarditis, pericarditis, left ventricular dysfunction without myocarditis, and others ([@B73]). The latter includes asymptomatic noninflammatory left ventricular dysfunction ([@B103]), Takotsubo-like syndrome with both basal ([@B26]) and apical ([@B36]; [@B4]) variants, coronary vasospasm ([@B89]), arrhythmias ([@B106]), and myocardial infarction ([@B132]). Of all the cardiotoxicity-associated ICIs, myocarditis is the most common cardiotoxic reaction. Pericardial diseases and conduction diseases were reported in 15 and 12% of patients with ICI-related cardiotoxicity, respectively ([@B82]). One published study ([@B75]) on 964 patients between 2013 and 2017 indicated that 1.14% of patients developed myocarditis and 0.52% developed a major adverse cardiovascular event (MACE), such as complete heart block, cardiogenic shock, and cardiac arrest, during treatment with ICIs. As for the presentation of myocarditis, it is highly variable and nonspecific ([**Table 1**](#T1){ref-type="table"}). Based on previously published studies, the manifestations of cardiotoxicity range from subclinical disease with asymptomatic cardiac biomarker elevation, fatigue, and general malaise to chest pain, dyspnea, palpitations, multiorgan failure, cardiogenic shock, and cardiac arrest ([@B67]; [@B137]; [@B37]; [@B28]; [@B101]; [@B75]; [@B85]; [@B129]; [@B107]).

![Immune checkpoint inhibitor (ICI)-related cardiac toxicity and its underlying mechanism. Anatomically, ICI-related cardiac toxicity involves almost all parts of the heart. The myocardium is most sensitive to ICI toxicity, showing impaired heart function. The cardiac conduction system, vascular system, and pericardium are also influenced by ICIs. Many infiltrating cells including hyperactivated CD4+/CD8+ T lymphocytes and a few macrophages (CD68+ cells) can microscopically be found in the heart tissue of patients with ICI-related cardiac toxicity. The infiltrating T cells are regarded as the main cause of ICI-related cardiac toxicity. The production of inflammatory factors promotes T cell activity. Elevated PD-L1 expression on cardiac muscle cells and T cells also contributes to the ICI-related cardiac toxicity.](fphar-10-01350-g001){#f1}

###### 

Published case reports and case series of immune checkpoint inhibitor-associated cardiotoxicity.

  References   Patient   Medical history                                     Cancer type               Drug                                       Time of onset                                       Symptoms                                                      Cardiotoxicity                    Withdraw the drug                 Treatment                                                                                                                                                      Outcome
  ------------ --------- --------------------------------------------------- ------------------------- ------------------------------------------ --------------------------------------------------- ------------------------------------------------------------- --------------------------------- --------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------
  ([@B59])     68/M      Hypertension, Prostate cancer                       Melanoma                  Ipilimumab Nivolumab                       2 weeks after second dose                           Dyspnea, irregular heartbeats, achycardia                     Myocarditis                       YES                               Solumedrol 1 g/day divided into four doses for 3 days. Prednisone 2 mg/kg and decreasing the dose daily by 7.5%.                                               Death
  ([@B105])    66/F      NR                                                  Lung cancer               Nivolumab                                  Three doses                                         Chest pain                                                    Myocarditis                       NR                                Methylprednisolone (50 mg/day) iv for 3 days, plasmapheresis, abatacept (500 mg q2w for five doses)                                                            NR
  ([@B29])     71/F      NR                                                  Melanoma                  Pembrolizumab                              Second cycle of treatment                           Dyspnea                                                       Myocarditis, Cardiac arrhythmia   NR                                Methylprednisolone (1 g/day) iv for 3 days, then (2 mg/kg/day) mycophenolate mofetil (2 g/day), plasmapheresis, rituximab (375 mg/m^2^), alemtuzumab (30 mg)   NR
  ([@B25])     79/F      Asthma, Hypertension                                Lung cancer               Pembrolizumab                              After the third infusion                            Chest pain                                                    Pericarditis                      Yes (Drug was reintroduced)       Pyridostigmine (30 mg, five times daily), methylprednisolone (80 mg/day).                                                                                      Clinical recovery
  ([@B3])      72/M      Hypertension, CAD, smoking                          Lung cancer               Anti-PD-L1                                 78 days                                             Dyspnea, hypotension hypoxia                                  Pericarditis                      Yes                               NR                                                                                                                                                             Death
  ([@B3])      65/F      II-DM Hypertension, smoking                         Lung cancer               Anti-CTLA-4, anti-PD-1                     131 days                                            Loss of consciousness hypotension                             Arrhythmias                       Yes                               Pacemaker                                                                                                                                                      Death
  ([@B3])      57/M      Smoking                                             Lung cancer               anti-PDL1                                  98 days                                             Dyspnea, orthopnea, bilateral lower edema                     Cardiac tamponade                 Yes                               NR                                                                                                                                                             No additional toxicity after reintroduction
  ([@B78])     80/M      None                                                Kidney cancer             Nivolumab                                  After four cycles                                   Severe asthenia                                               Myocarditis, AF                   Yes                               Methylprednisolone (2 mg/kg/day IV)                                                                                                                            Death
  ([@B69])     73/M      PVD                                                 UC                        Pembrolizumab                              After 22 cycles                                     Sweats, fatigue, fever, severe pain in the right limb         Vasculitis                        Yes                               NR                                                                                                                                                             NR
  ([@B30])     78/F      Hypertension, Intermittent Asthma, PE, Depression   Melanoma                  Nivolumab                                  5 days after the first cycle                        Muscle weakness, dyspnea                                      Myocarditis                       Yes                               Methylprednisolone (1--1.5 mg/kg/day IV) to pulse steroid 1,000 mg/day IV, IGI (2 g/kg/day IV)                                                                 Deterioration
  ([@B70])     61/F      NR                                                  Lung cancer               Atezolizumab                               3 days after first dose of atezolizumab             Dyspnea, fatigue                                              Myocarditis                       NR                                Methylprednisolone 5 mg/kg/day IV, mycophenolate mofetil 1000 mg/day orally                                                                                    Deterioration
  ([@B112])    55/F      A thymectomy for thymoma                            Melanoma                  Nivolumab                                  After the second infusion                           Dysphagia, dyspnea, limb weakness                             Myocarditis                       Yes                               IGI for four cycles, steroid pulse plus two cycles of plasma exchange                                                                                          Symptoms improved
  ([@B104])    74/M      NR                                                  Lung cancer               Nivolumab                                  After the second infusion                           General malaise, appetite decrease, dyspnea                   MN                                Yes                               Large amount of catecholamine                                                                                                                                  Death
  ([@B110])    76/F      Psoriatic arthritis                                 T-cell lymphoma           Brentuximab and Nivolumab                  After the first infusion                            Fatigue, dyspnea, orthopnea                                   AHF                               Yes                               Solumedrol 1 mg/kg for 3 days, Impella implantation.                                                                                                           Deterioration
  ([@B21])     33/M      NR                                                  HL                        Nivolumab                                  After the eight infusion                            NR                                                            CHB, Myocarditis                  Yes                               Mycophenolate mofetil, steroids (1 to 2 mg/kg), IGI                                                                                                            Death
  ([@B2])      73/M      NR                                                  Malignant Mesothelioma;   Pembrolizumab;                             32 days later                                       Progressive dyspnea, fatigue                                  Myocarditis                       Yes                               Prednisolone 60 mg/day orally, permanent pacemaker, IGI, plasmapheresis                                                                                        Death
  ([@B2])      89/M      II-DM, Hypertension, Dyslipidemia, AF               Melanoma                  Pembrolizumab                              After the first dose                                Weakness, myalgias, and dyspnea                               Myocarditis                       Yes                               Methylprednisolone 1 g/day IV was started, then oral prednisone 60 mg twice daily, ATG                                                                         Death
  ([@B2])      65/F      Hypertension, MR                                    Lung cancer               Nivolumab                                  6 days later                                        Dyspnea, edema, bradycardia                                   ACS, ADHF                         Yes                               Methylprednisolone 1 g/day for 3 days, prednisone, furosemide, ATG                                                                                             Deterioration
  ([@B2])      67/M      CAD                                                 Melanoma                  Nivolumab                                  Three cycles later                                  Chest pain, palpitations                                      Myocarditis                       Yes                               Prednisone 80 mg BID for 5 days then tapering, infliximab, oral corticosteroids                                                                                Symptoms improved
  ([@B83])     79/M      AF                                                  Prostate cancer           Nivolumab                                  After 8 weeks                                       Blurred vision, pain, stiffness in the upper back             Myocarditis                       Yes                               Methylprednisolone 1 mg/kg/day and oral prednisone taper                                                                                                       Clinical recovery
  ([@B46])     42/M      HBV carrier                                         HCC                       Pembrolizumab                              After six circles                                   Fatigue, dizziness and anorexia                               Bradycardia                       Yes                               Cortisone 12.5 mg/day orally                                                                                                                                   Symptoms improved
  ([@B34])     47/F      CAD                                                 Melanoma                  Ipilimumab and Nivolumab, then Nivolumab   4 months                                            Dyspnea, achycardic, pulmonary edema                          HF, ASVT                          Yes                               Methylprednisolone 500 mg intravenous BID for 5 days), infliximab (10 mg/kg/day for 2 days)                                                                    Death
  ([@B120])    52/M      None                                                RCC                       Nivolumab and Ipilimumab                   Three circles later                                 None                                                          Myocarditis                       Yes (Nivolumab reintroduce)       Beta-blocker therapy                                                                                                                                           No subsequent clinical event
  ([@B12])     69/M      None                                                RCC                       Avelumab and Axitinib                      4 days after second dose                            Fatigue, constipation                                         Hypertension, Cardiac arrest      Yes                               Reduction of axitinib, amlodipine                                                                                                                              Death
  ([@B52])     67/M      NR                                                  Melanoma                  Nivolumab and Ipilimumab                   16 days after the first dose                        Dyspnea, cough, dyspnea on exertion                           ADHF, Arrhythmia, CHB             Yes                               Methylprednisolone 500 mg twice daily, ATG and permanent pacemaker implanted                                                                                   Deterioration
  ([@B24])     69/M      NR                                                  Lung cancer               Nivolumab                                  5 days after the 24th cycle                         Dyspnea, tachycardia, fever                                   Pericarditis, PT                  Yes                               Prednisone (1 mg/kg) for 2 weeks, gradually tapered for 8 weeks                                                                                                Clinical recovery
  ([@B26])     45/F      NR                                                  Melanoma                  Nivolumab and Ipilimumab                   5 days after the first infusion                     NR                                                            AHF, TLS                          NR                                Methylprednisolone, 1 g/day IV                                                                                                                                 Complete recovery
  ([@B26])     77/M      NR                                                  Melanoma                  Ipilimumab Nivolumab.                      After 3 perfusions                                  NR                                                            TLS                               NR                                Methylprednisolone 1 g/day IV for 3 days                                                                                                                       NR
  ([@B35])     41/F      Hashimoto's thyroiditis                             Melanoma                  Ipilimumab and Nivolumab                   6 days after four cycles                            Dyspnea                                                       Myocarditis                       Yes                               Methylprednisolone 1g/day for 3 days                                                                                                                           Symptoms improved
  ([@B134])    60/M      None                                                Melanoma                  Nivolumab                                  13 cycles later                                     Fatigue, fever                                                Fulminant Myocarditis             Yes                               Prednisolone pulse therapy was initiated at 1000 mg/d for 3 days, IGI at 50 g/d for 2 days                                                                     Symptoms improved
  ([@B76])     75/F      NR                                                  EMC                       Durvalumab and Tremelimumab                3 weeks after the first dose                        Difficulty ambulating, dyspnea                                Myocarditis, HF,CHB               Yes                               Methylprednisolone 1 mg/kg, mycophenolate mofetil 1,000 mg oral twice daily                                                                                    Symptoms improved
  ([@B90])     55/F      NR                                                  Breast cancer             Pembrolizumab                              Five cycles later                                   Pericardial chest pain                                        PT                                Yes                               Anterior pericardiectomy, corticosteroids 2 mg/kg/day IV and keep low doses                                                                                    Symptoms improved
  ([@B33])     76/F      CD                                                  Lung cancer               Nivolumab                                  After seven biweekly administrations of Nivolumab   Rapidly progressive dyspnea                                   Myocarditis, CAB                  Yes                               Methylprednisolone 5 mg/kg/d and three doses of infliximab 5 mg/kg                                                                                             Deterioration
  ([@B117])    72/M      NR                                                  Melanoma                  Nivolumab and Ipilimumab                   After the 10th therapy                              Dyspnea, edema of the legs                                    Myocarditis                       Yes (Pembrolizumab reintroduce)   Prednisolone 1 mg/kg/day                                                                                                                                       Cardiacarrest
  ([@B58])     73/M      Smoking                                             Lung cancer               Pembrolizumab                              16 days after first dose                            Faintness                                                     CAB, Myocarditis                  NR                                Methylprednisolone, 1g/day IV for 3 days and temporary pacemaker implantation                                                                                  NR
  ([@B22])     43/M      NR                                                  Thymoma                   Nivolumab                                  10 days later                                       Chest discomfort, fatigue, myalgias of lower limbs            Myocarditis                       Yes                               IGI 300 mg/kg IV for 4 days, methylprednisolone 1 g/day for 3 days followed by 500 mg/day for 4 days then 60 mg/day                                            Death
  ([@B80])     55/M      Hypertension, COPD                                  Lung cancer               Nivolumab                                  3 days after the second dose                        Lethargy, dyspnea                                             ADRHF, cardiogenic shock          Yes                               NR                                                                                                                                                             Death
  ([@B88])     49/F      Hyperlipidemia                                      Melanoma                  Nivolumab and Ipilimumab                   2 weeks after the first dose                        Atypical chest discomfort at the cardiac apex                 Myocarditis                       Yes (following the Ipilimumab)    Methylprednisolone was initiated at 125 mg/day IV, IGI 400 mg/kg/day IV for 2 days                                                                             Clinical recovery
  ([@B6])      35/F      NR                                                  Melanoma                  Ipilimumab                                 15 days after the first infusion                    Progressive dyspnea                                           Fulminant Myocarditis             Yes                               Methylprednisolone, 1 g/day IV, and IGI IV, plasma exchanges                                                                                                   Completely recovered
  ([@B93])     61/M      Dyslipidemia, Smoking                               Lung caner                Nivolumab                                  After the 11th dose                                 NR                                                            ACS                               Yes                               Corticosteroids                                                                                                                                                Recovered
  ([@B60])     54/M      NR                                                  Lung cancer               Nivolumab                                  4 weeks after PD-1 therapy                          Dizziness, nausea, loss of consciousness, general paralysis   HF                                Yes                               High-dose steroid, pacemaker                                                                                                                                   Death
  ([@B11])     63/M      Hypertension, Hyperlipoproteinemia, II-DM, COPD     Melanoma                  Nivolumab                                  3 days after the second dose                        Dyspnea, dysphagia, worsened muscle pain                      AB, MI                            Yes                               Prednisone1.5 mg/kg IV and an antibiotic therapy with sultamicillin 3 g IV TID 500 mg aspirin and 5,000 IU unfractionated heparin                              Death
  ([@B54])     65/F      NR                                                  Melanoma                  Nivolumab and Ipilimumab                   12 days after the first doses                       Atypical chest pain, dyspnea, fatigue                         Fulminant myocarditis             Yes                               Methylprednisolone 1 mg/kg/day IV                                                                                                                              Death
  ([@B54])     63/M      NR                                                  Melanoma                  Nivolumab and Ipilimumab                   15 days after the first doses                       Fatigue, myalgias                                             Fulminant myocarditis             Yes                               Methylprednisolone 1 g/kg/day IV for 4 days and infliximab                                                                                                     Death
  ([@B103])    60/M      Hypertension, anxiety, RS                           Melanoma                  Ipilimumab                                 2 years after the first dose.                       None                                                          AF                                Yes                               Lisinopril 5 mg/day, metoprolol was changed to carvedilol 6.25 mg twice daily                                                                                  NR
  ([@B115])    69/F      NR                                                  Melanoma                  Nivolumab                                  2 months                                            General malaise, palpitation                                  Myocarditis                       Yes                               Oral prednisolone (2 mg/kg) was initiated                                                                                                                      Symptoms improved
  ([@B44])     72/M      MI, II-DM, Hypertension, PVD, Hyperuricemia         Melanoma                  Ipilimumab                                 After three infusions                               Dyspnea, anasarca                                             Myocarditis                       Yes                               Corticosteroids were initiated at 1 mg/kg orally                                                                                                               Symptoms improved
  ([@B44])     68/M      ADC, Alcohol abuse                                  Melanoma                  Ipilimumab                                 After four doses                                    Dyspnea, lower extremity edema                                Cardiomyopathy                    Yes                               Diuresis, coronary catheterization                                                                                                                             Resolved
  ([@B44])     71/M      None                                                Melanoma                  Ipilimumab                                 After the second infusion                           No obvious cardiac symptoms                                   MF                                Yes                               High dose steroids (2 mg/kg)                                                                                                                                   Death
  ([@B44])     81/M      AF, CAD                                             Melanoma                  Ipilimumab                                 11 weeks following the third dose                   Progressive subacute dyspnea                                  HF, Myocarditis                   Yes                               Diuretics                                                                                                                                                      Symptoms improved
  ([@B44])     23/M      NR                                                  Melanoma                  Ipilimumab                                 7 months after initiating Ipilimumab                Chest pain and cough                                          Myocarditis/HF                    Yes                               Methylprednisolone (2 mg/kg/day) converted to 80 mg prednisone/day with taper over 1 month,                                                                    Resolved to baseline
  ([@B44])     64/M      PVD                                                 Melanoma                  Ipilimumab                                 After the second dose                               Fatigue, seizures, abdominal pain ([@B137])                   Myocarditis                       Yes                               Dopamine and fentanyl                                                                                                                                          Death
  ([@B44])     88/M      CAD                                                 Melanoma                  Pembrolizumab                              After the eight infusion                            Myalgia, pain in the shoulder                                 Cardiac arrest                    Yes                               Corticosteroids 125 mg IV for 4 days                                                                                                                           Resolved
  ([@B44])     80/M      Melanoma                                            NHL                       Ipilimumab                                 2 weeks after two doses                             Dyspnea, edema, arrhythmias                                   Fatal myocarditis                 Yes                               Methylprednisolone (1 mg/kg) IV then prednisone 60 mg by mouth daily                                                                                           Death
  ([@B67])     73/F      NR                                                  Melanoma                  Pembrolizumab                              Five cycles later                                   Progressive dyspnea                                           AHF                               Yes                               AT2-receptor blocker, a beta-blocker, spironolactone, diuretics                                                                                                Symptomatic recovery
  ([@B137])    59/M      None                                                Melanoma                  Ipilimumab                                 12 weeks after four cycles                          Chest pain and dyspnea                                        AFP                               Yes                               Methylprednisolone 125 mg/day, prednisone 40mg/day, budesonide 9 mg/day on the third day, and tapered down over a month                                        Symptoms improved

NR, no report; HL, Hodgkin lymphoma; NHL, non-Hodgkin's lymphoma; UC, urothelial carcinoma; HCC, hepatocellular carcinoma; RCC, renal cell carcinoma; EMC, endometrial cancer; AF, atrial fibrillation; MN, myocardial necrosis; HF, heart failure; AHF, acute heart failure; CHB, complete heart block; ACS, acute coronary syndrome; ADHF, acute decompensated heart failure; ASVT, asymptomatic supraventricular tachycardia; PT, pericardial tamponade; TLS, Takotsubo-like syndrome; CAB, complete atrioventricular block; ADRHF, acute decompensated right-sided heart failure; AB, atrioventricular block; MI, myocardial infarction; MF, myocardial fibrosis; AFP, acute fibrinous pericarditis; IV, intravenous; ATG, anti-thymocyte globulin; QD, once daily; BID, twice daily; TID, three times per day; II-DM, diabetes mellitus type II; RS, Raynaud syndrome; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; PVD, peripheral vascular disease; AF, atrial flutter; MR, mitral regurgitation; ADC, asymptomatic dilated cardiomyopathy; CD, cardiovascular disease; PE, pulmonary embolism; mAb, monoclonal antibody; IGI, immunoglobulin.

As for the incidence and severity of cardiotoxicity, it is still not well recognized due to limited small-sample retrospective analyses and case reports regarding cardiotoxicity induced by ICIs. A multicenter retrospective study of 752 patients with melanoma treated with ipilimumab had shown that only one case of myocardial fibrosis had occurred ([@B126]). Despite the lack of prospective randomized controlled trials to assess myocarditis, retrospective evaluation literature has estimated that the incidence of ICI-related myocarditis ranges from 0.09 ([@B54]) to 1.14% ([@B75]). Although cardiotoxicity is rare, a high case fatality rate (35%) of myocarditis from ICIs had been reported in a systematic review by Hassan Mir ([@B82]). A systematic review by Wang et al. of fatal toxic effects associated with ICIs had found that ICI-related myocarditis appeared to present the highest (39.7%) death rate, with 52 deaths among 131 cases ([@B129]).

In patients treated with the combination of two ICIs, the incidence and death rate of cardiotoxicity is higher than with immunotherapy alone ([@B66]). The largest study of ICI-associated cardiotoxicity to date, using the global database (VigiBase) of the World Health Organization, has revealed that the incidence of myocarditis in patients treated with ICIs is 11 times greater than those without ICI treatment ([@B106]). A significantly higher case fatality rate (46%) in combination therapy was reported in this study. In addition, myocarditis was found to be more frequent (0.27 *vs.* 0.06%) and severe (60 *vs.* 10%) in patients prescribed a combination of nivolumab and ipilimumab than in those prescribed nivolumab alone ([@B54]). For the adverse events induced by the combination of nivolumab and ipilimumab, the rates of 1.3% for tachycardia, 1.1% for hypertension, 0.4% for arrhythmias, and 0.2% for atrial fibrillation were reported by the European Medicines Agency's European public assessment report, Opdivo ([@B42]). Nevertheless, when ICIs are combined with other non-ICI therapies, it remains unknown whether ICI-related myocarditis is more frequent. In a phase 1b trial of 55 patients treated with avelumab (anti-PD-L1 monoclonal antibody) plus axitinib (a vascular endothelial growth factor \[VEGF\] inhibitor), only one (1.8%) case developed lethal myocarditis ([@B23]).

The time to onset of cardiotoxicity presentation varies depending on the medical history, type of medication, duration of usage, and double or single medication ([**Table 1**](#T1){ref-type="table"}). Approximately 80% of ICI-associated myocarditis occurs within the first 3 months of starting ICI therapy ([@B65]; [@B95]). Approximately 62--64% of patients received only one or two doses of ICIs before the onset of myocarditis ([@B84]; [@B8]). Cardiac disorders, including myocarditis, pericarditis, and cardiomyopathy are reported to occur between 2 and 17 weeks after ICI treatment onset ([@B128]; [@B90]). An analysis of an eight-center institutional registry indicated the median time for myocarditis was 34--65 days after initiation of treatment ([@B75]). In contrast, a patient with melanoma had been reported to develop pericarditis 3 months after four cycles of ipilimumab ([@B137]). Interestingly, patients without any obvious symptoms had been found to have fulminant myocarditis after 1 year of ICI treatment ([@B134]). We reviewed previously published cases of adverse cardiac reactions and found that the onset time of cardiotoxicity was earlier in the combination of two ICIs. In the combination of two ICIs, in more than half (53%) of patients, cardiac toxicity occurred within 4 weeks after ICI initiation, whereas in ICIs alone, cardiac toxicity occurred in 17% of patients around the first ICI dose, and it occurred in 34% of patients 4 months later ([**Figure 2**](#f2){ref-type="fig"}).

![Time to onset of immune checkpoint inhibitor-related cardiac toxicity. In reported cases or case series, reagents including PD-1 inhibitors (nivolumab and pembrolizumab), PD-L1 inhibitors (atezolizumab, avelumab, and durvalumab), and CTLA-4 inhibitors (ipilimumab and tremelimumab) are used solely or in combination. This figure is built based on the cases' therapy types (monotherapy and combined therapy). The time when the ICI-related cardiac toxicity occurred since the first dose of each case is recorded as a dot. The time to onset of monotherapy (the blue dot) and combined therapy (the red dot) are illustrated. The onset time trend of ICI-related cardiac toxicity in each group is shown. On the right, two pie charts reveal case percentages of different onset time periods in each group.](fphar-10-01350-g002){#f2}

Potential Mechanism of Immune Checkpoint Inhibitor-Related Cardiac Toxicity {#s3}
===========================================================================

The mechanism of ICI-related cardiac toxicity is not yet fully understood. Histological analyses of patients and monkey models with ICI-associated myocarditis have revealed that the infiltration of predominant CD4^+^/CD8^+^ T lymphocytes and a few macrophages (CD68^+^ cells) are the main cause of ICI-associated myocarditis ([@B54]; [@B35]; [@B53]) ([**Figure 1**](#f1){ref-type="fig"}). In addition, the expression change of multiple chemokine receptors further proves the enhancement of T cells. CXCR3--CXCL9/CXCL10 and CCR5/CCL5 are required for T cell activities to upregulate ([@B122]; [@B53]). Tumor necrosis factor-α, granzyme B, and interferon-γ are produced by activated T cells, inducing cell death. These inflammatory molecules are overexpressed, which might contribute to cardiac injury ([@B125]; [@B121]).

The most likely explanation is the "shared antigen" between the tumor and cardiac muscle, with muscle-specific antigens (desmin and troponin) detected in the tumor. Moreover, similar clonal T cell populations have been found infiltrating tumors and cardiac muscle. In this case, hyperproliferative T lymphocytes and macrophages aberrantly infiltrate the cardiac muscle after treatment with ICIs, thereby inducing fatal myocarditis ([@B54]). This theory is also supported by the shared epitope between myeloma cells and cardiomyocytes ([@B79]).

Like tumor cells, cardiomyocytes might also employ the PD-1/PD-L1 and CTLA-4 pathways to prevent T cells from hyper-activation in physiological condition. ICIs, a promising anti-cancer agent, liberate the T-cell inhibition by tumor cells, may also relieve the same type of suppression by cardiomyocytes, which leads to T-cell hyperactivation in the heart. Subsequently, T-cell hyperactivation may result in ICI associated cardiotoxicity. CD28 binds to CD80 (B7-2)/CD86 (B7-2) on antigen-presenting cells (APCs) as a second activation signal to stimulate TCR signaling. CTLA-4 can complete with CD28 for binding with CD80/86 to inhibit the immune response. In contrast, silencing the genes that encode CTLA-4 promotes the proliferation and infiltration of CD8^+^ T cells in the heart, contributing to the development of myocarditis ([@B71]). In many preclinical models, PD-1 has also been demonstrated to limit the T cell response in the heart as a negative immunoregulatory receptor. The disruption of PD-1 induces CD8^+^ T cell-mediated autoimmune dilated cardiomyopathy and myocarditis ([@B86]; [@B130]), suggesting PD-1 is protective against inflammation and cardiac damage ([@B118]).Similarly, the knockdown of PD-L1 also leads to mortal autoimmune myocarditis in a preclinical model of Murphy Roths Large mice ([@B72]). Moreover, in patients with injured myocardium, PD-L1 is overexpressed on injured cardiomyocytes and infiltrating CD8^+^ T cells ([@B54]). Consistently, in preclinical studies of T cell-mediated myocarditis, the expression of PD-L1 is also upregulated ([@B38]).The upregulation of PD-L1 might protect the myocardium from damage; however, this upregulation can be neutralized by ICIs ([@B38]). In summary, these limited findings indicate that PD-1/PD-L1 and CTLA-4 play crucial roles in the emergence and development of ICI-related cardiac toxicity. Further studies are needed to elucidate the underlying mechanisms of these effects.

The Diagnosis of Immune Checkpoint Inhibitor-Associated Cardiotoxicity {#s4}
======================================================================

The detection of ICI-associated cardiotoxicity is currently challenging due to the lack of consistency of its clinical manifestation ([**Table 1**](#T1){ref-type="table"}). If ICI-related cardiotoxicity is observed in a patient, a detailed history and physical exams are required to exclude alternative cardiomyopathy etiologies, such as viral and autoimmune cardiac disease, infectious myocarditis or myocardial infarction. This comprehensive diagnostic information is helpful to correct circulation in a timely manner, to provide patients with specific treatment, and to help improve their symptoms ([@B18]).

For early diagnosis of subclinical myocarditis, serial laboratory tests, electrocardiograms (ECGs) and transthoracic echocardiograms (TTEs) can be beneficial for patients treated with ICIs. Laboratory tests typically include troponin (cardiac troponin I \[cTnI\] or troponin T \[cTnT\]), creatine phosphokinase (CPK), creatine kinase (CK), creatine kinase-myocardial band (CK-MB), brain natriuretic peptide (BNP), and N-terminal pro-brain natriuretic peptide (NT-proBNP) ([**Table 2**](#T2){ref-type="table"}). Of all the markers, troponin is generally the most sensitive marker for confirming or excluding the diagnosis of myocarditis ([@B7]). Mahmood et al. have indicated that almost all (94%) myocarditis cases had elevated troponin at the time of manifestation ([@B75]). We reviewed the previous cases/case series and found that 84 and 89% of patients with ICI-associated cardiotoxicity had elevated cTnI and abnormal ECG, respectively ([**Figure 3**](#f3){ref-type="fig"}). Even very low serum concentrations of troponin can provide important diagnostic and/or prognostic information for oncologists ([@B50]; [@B74]; [@B27]). Notably, in patients with myositis, cTnT and CPK can also be elevated; thus, cTnI is the preferred marker for cardiac injury ([@B48]). Interestingly, Mahmood et al. have also indicated that higher levels of serum cTnT might be associated with a greater risk of MACE ([@B75]). BNP or NT-proBNP, the sensitive indicators ([**Figure 3**](#f3){ref-type="fig"}), were reported to increase in most patients ([@B73]); these are also helpful for the diagnosis of ICI-associated cardiotoxicity ([@B88]). In cynomolgus monkeys with moderate mononuclear cell infiltration or with myocardial degeneration, an NT-proBNP or cTnI increase was observed at multiple time points after the first dose of ICIs; thus, they might serve as valuable biomarkers for ICI-induced myocarditis ([@B53]). However, BNP is a poorly specific marker for the diagnosis of ICI-associated cardiotoxicity, because it not only can be elevated in noninflammatory left ventricular dysfunction or other causes of acute cardiac injury, but also in many patients with cancer who have cardiotoxicity ([@B10]). The elevation of CK can also be observed in ICI-induced myocarditis ([**Figure 3**](#f3){ref-type="fig"}) ([@B22]; [@B2]; [@B112]). Moreover, several reports have indicated that a complete atrioventricular block is usually associated with ICI-related myocarditis, with a considerably elevated CK level ([@B44]; [@B54]). Of note, mild to massive elevation of serum CK was found in patients diagnosed with ICI-related myositis or myasthenia gravis ([@B61]; [@B20]; [@B113]; [@B77]); therefore, the specificity of elevated CK was relatively poor.

###### 

Laboratorial, radiological, and histopathological features of immune checkpoint inhibitor-associated cardiotoxicity.

  Laboratory tests                          ECG                                                                                                           TTE                                                                                               CMR                                                                                                                              Histopathological features
  ----------------------------------------- ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  cTnI mildly elevated (a\* = 9)            Sinus bradycardia (k\* = 2)                                                                                   LVSF diminished ([@B78])                                                                          T2 intramyocardial intensity consistent with edema ([@B2])                                                                       Inflammatoryinfiltrate beneath the thick fibrinous layeron the epicardium (CD4^+^, CD8^+^ T cells, some CD68^+^ macrophages, scattered CD20^+^ B cells ([@B3])
  cTnI moderately elevated (b\* = 7)        Sinus tachycardia with ST-segment elevation in V1-6 ([@B104])                                                 Reduced LVEF of 9% and akinesis of anteroseptal wall and apex ([@B104])                           An elevated regional T2 ratio and EGE ([@B2])                                                                                    Myocardial necrosis ([@B78])
  cTnI massively elevated (c\* = 8)         Sinus tachycardia with no ST-T changes ([@B52]; [@B110])                                                      Severely reduced LVEF, moderate PE, moderate MR, severe TR and mildly RVD ([@B110])               A non-ischemic pattern of LGE, four-chamber dilation with severe biventricular dysfunction ([@B34])                              Intense inflammatory infiltrate: CD3^+^, CD8^+^, CD4^+^, 40% of all lymphocytes were PD-1 positive, some CD68^+^ macrophages ([@B78])
  cTnT elevated ([@B67]; [@B134])           Atrial rate was faster than ventricular rate ([@B21])                                                         Mild concentric LVH, mild RAE, moderate LAE, and mild AR, MR, TR ([@B2])                          Patches of LGE were seen in the basal and mid inferior wall showing an epicardial pattern compatible with myocarditis ([@B83])   Myocardial necrosis with few inflammatory cells scattered in both ventricles ([@B104])
  cTnI decreased ([@B70])                   Alternating RBBB and LBBB, episodes of asystole, third-degree block with a junctional escape rhythm ([@B2])   RVD ([@B2])                                                                                       Diffuse myocardial edema ([@B26])                                                                                                Intense inflammatory infiltrate: CD4^+^, CD8^+^ T cells. PD-L1 stain showed focal membrane positivity in the areas of LGE ([@B34])
  CK mildly elevated ([@B58])               RBBB ([@B2])                                                                                                  EF was severely decreased to 25--30% ([@B2])                                                                                                                                                                                       Lymphocytic infiltrate: CD3^+^, CD4^+^, CD8^+^ T cells, CD68^+^ macrophage within the myocardium, cardiac sinus and atrioventricular nodes ([@B54])
  CK moderately elevated (d\* = 7)          Sinus rhythm with new lateral ST segment depressions ([@B2])                                                  Mild BVD with reduced RVSF, BAD ([@B2])                                                                                                                                                                                            T-cell and macrophage infiltrates in the myocardium, cardiac conduction system and skeletal muscle ([@B54])
  CK massively elevated ([@B22]; [@B2])     Atrial tachycardia ([@B34])                                                                                   GBF with LVEF of 26%, severe LVD ([@B30]), and a trivial PE ([@B34])                                                                                                                                                               Heavy infiltration of CD68^+^ and CD3^+^, CD20^-^ T-lymphocytes ([@B12])
  CPK mildly elevated ([@B104])             PR prolongation with normal QRS complexes ([@B54])                                                            LVEF of 65% with LAE, RVD and increased PAP ([@B54])                                                                                                                                                                               Diffuse cardiomyocyte necrosis with lymphocytic infiltration and predominance of CD3^+^ and CD20^-^ T cells ([@B52])
  CPK moderately elevated (e\* = 3)         Profound ST segment depression ([@B54])                                                                       Severe LV hypokinesis and LVEF decline to 20% ([@B52]).                                                                                                                                                                            Nonspecific chronic inflammation with extensive fibrosis and lymphocyte infiltration ([@B24])
  CPK massively elevated ([@B54]; [@B58])   AF with QT prolongation and LAFB ([@B83])                                                                     Restrictive PE ([@B24])                                                                                                                                                                                                            Diffuse infiltration with inflammatory cells (histocytes, lymphocytes, macrophages, and giant cells) with cardiac myocyte necrosis ([@B82])
  CK-MB mildly elevated (f\* = 5)           Complete atrioventricular block with wide QRS complexes ([@B58])                                              Reduced LVEF (40%) with apical and mid-ventricular akinesia ([@B26])                                                                                                                                                               Lymphocytic infiltration: CD3^+^, CD4^+^, CD8^+^ CD20^-^, strong expression of PD-L1 ([@B22])
  CK-MB moderately elevated (g\* = 3)       Intraventricular conduction delay progressed into episodes of ventricular tachycardia ([@B52])                GlobalLV systolic dysfunction with an EF of 15% ([@B35])                                                                                                                                                                           Extensive lymphocytic infiltration, interstitial edema, and myocardial necrosis and with predominant CD4^+^, CD8^+^, CD20^-^, PD-L1 strongly expressed on myocardium ([@B134])
  CK-MB massively elevated ([@B54])         Sinus tachycardia with T-wave inversion in the anteroseptal leads ([@B26])                                    Thickened interventricular septum (12 mm), regular ventricular motion with LVEF of 49% ([@B22])                                                                                                                                    Lymphocytic infiltration with occasional eosinophils ([@B76])
  BNP mildly elevated (h = 5\*)             T-wave inversion on leads V2, V3, and V4 ([@B26])                                                             Diffuse hypokinesis and reduced LVEF (15%) with myocardial edema ([@B134])                                                                                                                                                         Diffuse lymphoplasmacytic infiltrates (CD3^+^, CD4^+^, CD8^+^, CD20^-^ cells) with foci of active myocyte injury and necrosis throughout the atria, ventricles, and interventricular septum, ([@B80])
  BNP moderately elevated (i = 4\*)         Low QRS voltage and T wave inversion on V1--V4 leads ([@B137])                                                54% LVEF with regional areas of hypokinesis ([@B76])                                                                                                                                                                               CD3^+^ infiltrated in the pericardium; huge infiltration in pericardium with predominance of neutrophils ([@B90])
  BNP massively elevated ([@B2])            Sinus rhythm with prolongation of the PR interval and RBBB ([@B22])                                           RVD with reflux into the hepatic veins, suggestive of RHF ([@B80]).                                                                                                                                                                Interstitial fibrosis with inflammation, fiber necrosis, signs of hypertrophy ([@B117])
  NT-pro BNP elevated (j = 5\*)             ST segment Elevation in V4--V6, leads II, III, and aVF ([@B134])                                              Moderate PE and right atrial systolic collapse ([@B90])                                                                                                                                                                            Early collagen deposition admixed with inflammatory cells; the majority of CD3^+^, CD4^+^, CD68^+^; the rarity of CD20^+^, CD138 ([@B88])
  CRP mildly elevated ([@B58]; [@B30])      CAB ([@B60]; [@B76])                                                                                          A severely reduced LVEF, MAB ([@B33])                                                                                                                                                                                              Lymphocytic infiltration: CD3^+^, CD8^+^ cells with the myocardium ([@B54])
  CRP massively elevated ([@B78])           Sinus tachycardia ([@B90])                                                                                    Diffuse hypokinesis of the LVEF (30.2%) ([@B57])                                                                                                                                                                                   Lymphocytic infiltration with a predominance of CD8+ T cells ([@B57])
  AChR Ab mildly elevated ([@B78])          Sinus tachycardia with a RBBB and ST-segment elevation in the anteroseptal and inferolateral leads ([@B6])    A severely impaired LVEF of 30% with marked ventricular desynchrony ([@B67])                                                                                                                                                       Patchy lymphocytic infiltration: CD3^+^, CD8^+^, CD68^+^ cells ([@B44])
  AChR Ab massively elevated ([@B112])      ST-segment elevation in leads II, III, and aVF ([@B57])                                                                                                                                                                                                                                                                                          Lymphocytic infiltration with a predominance of CD8^+^ T cells ([@B67])
                                            A suspected non-ST segment elevation MI ([@B11])                                                                                                                                                                                                                                                                                                 Mixed inflammatory infiltrates in the pericardial wall, accompanied by abundant surface fibrin ([@B137])
                                            PR interval prolongation with normal QRS complexes; rapid progression to CHB ([@B54])                                                                                                                                                                                                                                                            
                                            Tachycardiac sinus rhythm with ventricular bigamy ([@B67])                                                                                                                                                                                                                                                                                       

Compared with the normal value of laboratory tests: mildly elevated: \< 10 times; moderately elevated: ≥10 and \<100 times; massively elevated: ≥100 times. cTnI, cardiac troponin I; cTnT, cardiac troponin T; BNP, brain natriuretic peptide; TTE, transthoracic echocardiogram; ECG, electrocardiogram; CMR, cardiovascular magnetic resonance; CK-MB, creatine kinase-myocardial band; NT-pro BNP, N-terminal pro-brain natriuretic peptide; CPK, creatine phosphokinase; CK, creatine kinase; CRP, C-reactive protein; AChR Ab, acetylcholine receptor antibody; EF, ejection fraction; LV, left ventricular; LVEF, left ventricular ejection fraction; PE, pericardial effusion; MR, mitral regurgitation; AR, aortic regurgitation; BVD, bi-ventricular dilatation; BAD, bi-atrial dilatation; LVD, left ventricle dilatation; RVD, right ventricle dilatation; TR, tricuspid regurgitation; LAFB, left anterior fascicular block; LBBB, left bundle branch block; RBBB, right bundle branch block; LVH, left ventricular hypertrophy; RAE, right atrial enlargement; LAE, left atrial enlargement; GBF, global biventricular failure; LGE, late gadolinium enhancement; EGE, early gadolinium enhancement AF, atrial fibrillation; PAP, pulmonary artery pressure; LVSF, left ventricular systolic function; RVSF, right ventricular systolic function; RHF, right heart failure; CHB, complete heart block; MI, myocardial infarction; MAB, multiple apical thrombi; CAB, complete atrioventricular block

(a\* = 9 ([@B88]; [@B35]; [@B58]; [@B83]; [@B120]; [@B2]; [@B21]; [@B104]; [@B110]).

(b\* = 7) ([@B26]; [@B33]; [@B80]; [@B2]; [@B21]; [@B30]; [@B59]).

(c\* = 8) ([@B54]; [@B6]; [@B22]; [@B78]; [@B105]).

(d\* = 7) ([@B6]; [@B83]; [@B134]; [@B2]; [@B78]; [@B105]; [@B112]).

(e\* = 3) ([@B11]; [@B60]; [@B59]).

(f\* = 5) ([@B88]; [@B22]; [@B58]; [@B70]; [@B104]).

(g\* = 3) ([@B54]; [@B83]; [@B2]).

(h\* = 5) ([@B67]; [@B83]; [@B2]; [@B30]; [@B110]).

(i\* = 4) ([@B34]; [@B70]; [@B78]; [@B104]).

(j\* = 5) ([@B22]; [@B33]; [@B35]; [@B70]; [@B105]).

(k\* = 2) ([@B46]; [@B70]).

![Summarized results of laboratory tests and other examinations for diagnosis in published cases reports/case series. The laboratory tests include cTnI, cTnT, CK, CK-MB, CPK, BNP, NT-pro-BNP. Other examinations include ECG, TTE, CMR, CAG, PET/CT, and EMB. No tests\* means no laboratory testing or examination is performed in cases. Compared with the normal value of laboratory tests: Lowly abnormal: 10 times; Moderately abnormal: ≥10 and 100 times; Highly abnormal: ≥100 times. cTnI, cardiac troponin I; cTnT, cardiac troponin T; CPK, creatine phosphokinase; CK, creatine kinase; CK-MB, creatine kinase-myocardial band; BNP, brain natriuretic peptide; NT pro BNP, N-terminal pro-brain natriuretic peptide; ECG, electrocardiograph; TTE, transthoracic echocardiogram; CMR, cardiovascular magnetic resonance; CAG, coronary angiography; PET/CT, positron emission tomography/computed tomography; EMB, endomyocardial biopsy.](fphar-10-01350-g003){#f3}

Given ECG has widespread availability and is easy to perform, it is considered a first-line test to identify patients with suspected ICI-associated myocarditis ([@B35]). In our review of previous case reports, most patients had had an ECG performed ([**Figure 3**](#f3){ref-type="fig"}). Abnormal ECGs have been reported in 40--89% of patients with ICI-related cardiotoxicity; however, these changes are often nonspecific ([**Table 2**](#T2){ref-type="table"}) ([@B28]; [@B75]). TTE has also been applied to provide further insight into left ventricular ejection fraction (LVEF) impairment, pericardial effusions, and wall motion abnormalities. However, a normal TTE report does not rule out ICI-associated myocarditis ([@B85]; [@B121]). Patients presenting with cardiac marker elevation, ST elevation, and ischemic symptoms should receive emergency coronary angiography to eliminate acute coronary syndrome ([@B116]).

To accurately diagnose myocarditis, further diagnostic technologies, such as cardiac magnetic resonance (CMR) imaging or an endomyocardial biopsy (EMB) are also necessary ([@B39]; [@B9]). Gadolinium contrast-enhanced CMR imaging, a meaningful noninvasive diagnostic tool superior to echocardiography, can identify tissue characterization and offer accurate diagnosis of fibrosis and inflammation for hemodynamically stable patients in the early course of the disease ([@B32]; [@B5]). The CMR features of myocarditis, including edema, necrosis, and scar formation, were previously defined as the Lake Louise Criteria ([**Table 2**](#T2){ref-type="table"}) ([@B32]). For instance, an enhanced T2 signal on CMR could be indicative of underlying myocardial edema or myocarditis ([@B110]). However, for patients who require invasive hemodynamic or respiratory and/or circulatory support, CMR imaging might not be feasible. Furthermore, although CMR imaging to detect myocardial edema and late gadolinium enhancement is accurate, its sensitivity is relatively poor ([@B67]; [@B28]; [@B88]; [@B75]) and an absence of positive findings on CMR does not rule out myocarditis ([@B1]).

EMB, a gold standard for the diagnosis of myocarditis ([@B62]; [@B68]; [@B16]), should be conducted when the treatment course is affected by suspected cardiotoxicity. This is especially true in unclear situations in which the oncologist does not know whether to continue or terminate ICI treatment. An EMB can reveal various features of interstitial inflammation suggested by interstitial fibrosis and lymphocyte infiltration ([@B110]). Previous reports on ICI-related myocarditis have shown that significant T cells (CD4^+^, CD8^+^) and macrophage infiltration were observed in the myocardium ([@B67]; [@B44]; [@B54]; [@B63]; [@B115]), cardiac conduction system ([@B54]), interventricular septum ([@B80]) and pericardium ([@B90]) ([**Table 2**](#T2){ref-type="table"}). Similar T cell populations were also observed in cardiomyocytes, according to a postmortem report of a patient who died from ICI-induced myocarditis ([@B54]), suggesting hyperactivated cytotoxic T cells directly injuring themyocardium as the probable mechanism of myocarditis induced by ICIs. B lymphocytes and/or plasma cells are usually rare or absent ([@B3]). Inflammatory infiltration can be transient and focal, however, and can sometimes be inaccessible to pathological puncture. Therefore, a biopsy sampling error from patients with myocarditis can result in a false negative diagnosis ([@B68]). In this case, it is suggested that EMB should be reattempted in cases with unexplained progressive heart failure ([@B16]).

Treatment and Outcome of Immune Checkpoint Inhibitor-Associated Cardiotoxicity {#s5}
==============================================================================

The treatment regimens for ICI-associated cardiotoxicity vary depending on the case ([**Table 1**](#T1){ref-type="table"}); however, the principal strategy concentrates on targeting the hyperactive T-cell response. High-dose steroids have constituted the first-line treatment for ICI-related myocarditis ([@B44]; [@B54]; [@B61]; [@B108]; [@B115]; [@B40]; [@B15]). Prompt initiation of high-dose intravenous methylprednisolone and immediate ICI discontinuation are associated with improved symptoms ([@B28]; [@B75]). A higher starting dose of steroids (intravenous methylprednisolone 1 g) was related to a lower rate of MACE according to a recent study by Mahmood et al. ([@B75]). Although data regarding treatment for irAEs from rigorous studies are lacking, rapidly initiating intravenous or oral prednisone (1--2 mg/kg) for most patients and intravenous methylprednisolone (0.5--1.0g) for refractory cases with progressive tapering are recommended according to consensus guidelines ([@B15]). However, multiple studies have indicated that corticosteroids alone might not be sufficient to improve immune-mediated cardiac adverse reactions, and patients with ICI-associated cardiac events might even progress to malignant arrhythmias and severe heart failure symptoms during steroid treatment ([@B44]; [@B54]). Many patients had received corticosteroids early in their cardiotoxicity management, tapering them over 1 month; however, no significant effect was observed ([@B88]; [@B2]; [@B78]).

For patients with a poor response to corticosteroids, other immunosuppressive drugs should be administered, including immunoglobulin ([@B16]), plasmapheresis, mycophenolate mofetil, tacrolimus, and infliximab ([@B40]; [@B51]; [@B88]; [@B100]; [@B15]; [@B33]; [@B73]). Infliximab, a chimeric immunoglobulin G1 monoclonal antibody blocking tumor necrosis factor-α, is used to treat patients with steroid-refractory ICI-associated colitis ([@B91]). The use of infliximab has been documented in the context of severe steroid-refractory myocarditis ([@B44]; [@B54]; [@B119]; [@B33]) and has demonstrated significant clinical recovery and biochemical normalization ([@B2]). It is cautioned that infliximab could be potentially associated with deteriorating heart failure and is prohibited for patients with moderate to severe heart failure ([@B64]). Considering the histological similarity between ICI-associated myocarditis and cardiac transplantation rejection, anti-transplant rejection medications (e.g., anti-thymocyte globulin \[ATG\]) have also been used for treating patients with ICI-related myocarditis ([@B119]). One case series has indicated that two patients treated with ATG after their clinical course worsened during steroid treatment responded well to ATG therapy, with remission of cardiogenic shock and malignant arrhythmias ([@B2]). The underlying mechanism could be associated with ATG leading to a rapid reduction in lymphocyte infiltration and T cell superactivation, thereby resulting in myocardial conduction improvement ([@B119]).

Recently, two reports ([@B29]; [@B105]) have shown that the new therapeutic agents alemtuzumab and CTLA-4 agonists (abatacept and belatacept), could be associated with significant relief of symptoms of cardiotoxic reactions caused by ICIs. Alemtuzumab, a monoclonal antibody that binds to CD52, can result in destruction of complement-mediated peripheral immune cells (monocytes, lymphocytes, macrophages, natural killer cells, and dendritic cells). Although the use of alemtuzumab in the context of cardiac allograft rejection has previously been evaluated, data on its use in patients with irAEs is limited ([@B17]). A recent report has indicated that 30 mg of alemtuzumab led to rapid T-cell depletion and was associated with the resolution of cardiac immunotoxic effects ([@B29]). CTLA-4 agonists, either abatacept or belatacept, can inhibit T cell costimulation mediated by CD28/B7 at the dendritic cell level, thereby abrogating the costimulation of T cells upstream of PD-1/PD-L1 and the CTLA-4 pathways. Abatacept can rapidly cause global T cell anergy (the inactivation of normal immune response) with specific reverse pathways activated by ICIs ([@B49]). When high-dose methylprednisolone injection and sustained plasmapheresis did not work, abatacept resulted in a rapid reduction in cTnI levels and recovery of LVEF ([@B105]). However, given the potential risks of infectious complications and tumor growth, it is necessary to further evaluate of the risk--benefit balance of abatacept in ICI-induced myocarditis ([@B49]).

Apart from the immunosuppressive therapies above, when necessary, beta-blockers, angiotensin converting enzyme inhibitors (ACEIs), and high-dose aspirin could be required as auxiliary therapies for patients with heart failure and in the context of raised troponin and the indication of cardiac ischemia ([@B12]). Extracorporeal membrane oxygenation is also required for a patient with severe myocarditis induced by the combination therapy of nivolumab and ipilimumab ([@B6]).

Possible Management of Immune Checkpoint Inhibitor-Associated Cardiotoxicity and Future Directions {#s6}
==================================================================================================

Cardiotoxicity, a rare but fatal irAE, is particularly difficult to supervise and manage ([@B98]; [@B99]; [@B15]). Currently, no standard management guidelines on ICI-related cardiotoxicity have been established, due to its low incidence and the limited data on its manifestation, diagnosis, therapy, and outcomes. Based on previous studies and evidence, we summarized the possible management of ICI-related cardiotoxic reactions ([**Figure 4**](#f4){ref-type="fig"}) as follows.

![Summarized overview on potential monitoring and management of ICI-related cardiotoxicity. CK, creatine kinase; CK-MB, creatine kinase-myocardial band; BNP, brain natriuretic peptide; NT pro BNP, N-terminal pro-brain natriuretic peptide; TTE, transthoracic echocardiogram; CMR, cardiovascular magnetic resonance; EMB, endomyocardial biopsy; ATG, anti-thymocyte globulin; IGI, immunoglobulin; ACEI, angiotensin converting enzyme inhibitor.](fphar-10-01350-g004){#f4}

Before initiating ICI therapy, a comprehensive assessment of cardiovascular risk factors and a detailed cardiac history should be obtained for all patients, given the risk factors for ICI-associated cardiotoxicity remain unclear to date. According to previous reports, potential risk factors such as autoimmune disease, pre-existing cardiac disease, the combination of ICIs, and age should be evaluated before ICI treatment. In 50% of patients treated with ipilimumab, pre-existing autoimmune diseases worsened ([@B14]). Several studies have also revealed that patients with underlying autoimmune disease might be at high risk of irAEs, including cardiotoxicity ([@B56]; [@B55]; [@B96]). For instance, patients with systemic autoimmune disorders are more likely to have subclinical myocarditis than those without autoimmune diseases. These results show that clinical and subclinical autoimmune diseases are an important consideration before initiation of ICI therapy ([@B125]). Physicians should be aware of potentially cardiotoxic events during ICI treatment, especially for those with pre-existing cardiac conditions ([@B46]). In Heinzerling's report, pre-existing cardiac disease or peripheral arterial disease had been present in most patients (5 of 8) who developed autoimmune cardiotoxicity ([@B44]). The combination therapy of ICIs might also be a risk factor for ICI-associated myocarditis ([@B125]). Some VEGF inhibitors can increase the risk of thrombosis and coronary ischemia ([@B52]). They are also known to be related to cardiotoxicity and left ventricular dysfunction ([@B109]). Therefore, when ICIs are combined with anti-VEGF therapies, we should be vigilant for cardiac adverse effects. Given that the common adverse reaction to anti-VEGF therapies, such as axitinib, is hypertension ([@B41]), it is not a likely causal agent in case of myocarditis; however, it can result in poor heart function in reaction to the physiological challenge. In addition, age can be associated with the incidence of ICI-associated cardiotoxicity. In Wang's retrospective cohort, fatal irAEs involving cardiovascular toxicities were more common in the elderly than in the young (median,70 *vs* 62 years, *P* = .009) ([@B129]). Other risk factors, such as diabetes mellitus, a history of smoking, and dyslipidemia, might be included ([@B11]; [@B88]; [@B123]; [@B58]; [@B2]; [@B3]), however, large sample studies are needed for confirmation.

To accurately diagnose ICI cardiotoxicity, several appropriate steps can be taken into consideration: First, serum troponin tests, baseline ECG, and serial surveillance are necessary. TTE and other laboratory tests, such as CK, CK-MB, BNP, or NT-proBNP can also be performed. Notably, for some special cases with a high risk of cardiotoxicity, TTE is strongly recommended to record the patient's baseline cardiac function before the initiation of ICIs, and other laboratory inspections should be performed to record their baseline cardiac status. When a cardiotoxic reaction is suspected during treatment with ICIs alone and in combination---for example, the patient's symptoms might include chest pain, dyspnea, fatigue, palpitations, fever, and limb weakness---one major challenge for oncologists is to identify whether these symptoms are clinical manifestations of cardiovascular irAEs. In a highly suspected ICI-associated cardiotoxic event, temporary discontinuation of ICIs is suggested; it is then necessary for the oncologists, cardiologists, and immunologists to together discuss further diagnosis and treatment. Second, apart from cardiac troponin and ECG, other laboratory biomarker tests, such as serum CK, CK-MB, BNP, and NT-proBNP tests, are strongly proposed. Although a TTE must be performed to record the heart function, normal cardiac function does not rule out ICI-induced myocarditis. CMR is also advisable to further evaluate abnormal cardiac structure. When CMR is not available or contraindicated, cardiac positron emission tomography/computed tomography is beneficial to diagnose myocardial inflammation. Third, in uncertain cases, EMB should be performed and samples from multiple sites should be collected to optimize the diagnostic accuracy of focal myocarditis and reduce sampling errors ([@B68]). After a comprehensive diagnosis, if there is no evidence of cardiac dysfunction, myocarditis, or other cardiotoxic events, ICI therapy can be slowly reintroduced under close troponin and ECG monitoring.

For patients with confirmed ICI-associated myocarditis, permanent discontinuation of ICIs after cardiac adverse events (G1) has been recommended by the American Society of Clinical Oncology guidelines, though the recommendation is based on anecdotal evidence ([@B15]). Then, prompt administration of oral prednisone (1--2 mg/kg/day) ([@B51]) or intravenous methylprednisolone (1--2 mg/kg/day) ([@B98]; [@B128]; [@B15]; [@B24]) should be initiated. If improved signs are observed, a slow tapering dose of glucocorticoid over at least 4 weeks has been recommended ([@B47]). In patients with pericarditis, despite the resolution of pericardial effusion *via* pericardial window, prednisone (1 mg/kg) initiation approximately 2 weeks later can prevent constrictive pericarditis ([@B24]). For patients with sick sinus syndrome, a low dose of cortisone (12.5 mg/day) taken orally might help relieve symptoms ([@B46]). Nonetheless, if a patient shows a poor response to glucocorticoids, secondary drugs, including ATG, immunoglobulin, infliximab, tacrolimus, mycophenolate mofetil, rituximab, CTLA-4 agonists, and alemtuzumab can be considered ([@B51]; [@B88]; [@B100]; [@B33]; [@B29]; [@B105]). What should be emphasized is that infliximab is generally contraindicated because it can induce congestive heart failure ([@B64]). Although the safety and efficacy of these immunosuppressive agents (*e.g.*, ATG, alemtuzumab, abatacept, belatacept) need further confirmation, these drugs could be a viable choice, especially for a critically ill patient with rapidly deteriorating cardiovascular function when high-dose glucocorticoid therapy is not possible.

In parallel with the immunosuppressive agents above, guideline-based therapy and supportive care is recommended for patients with ICI-associated cardiotoxicity. Patients with congestive heart failure should be treated with tolerable medications, including renin-angiotensin system inhibitors and beta-blockers ([@B135]). Those with progressive life-threatening arrhythmias should be treated with appropriate antiarrhythmic drugs, or a patient with advanced conduction disease should be considered for temporary/permanent pacemaker placement. When necessary, invasive therapies such as pericardial window placement or pericardiocentesis might also be needed ([@B136]).

It is controversial whether immunotherapy should be reintroduced after recovery from cardiac toxicity ([@B15]). Although cardiac dysfunction can be significantly improved by high-dose glucocorticoid therapy, an anti-PD1 antibody rechallenge might aggravate immune-related toxicity ([@B117]). Given the potential for fulminant or fatal ICI-related myocarditis, ICIs are not recommended for reintroduction in patients ([@B19]). However, in a retrospective analysis of 30 patients who were diagnosed with cardiotoxic irAEs, four patients resumed ICIs safely, without cardiotoxic event recurrence ([@B28]).Therefore, the clinical oncologist, cardiologist, and immunologist collaboration should give discreet consideration to patients according to their manifestations, outcome, and alternative cancer treatment options to determine the safety of reintroducing ICI therapy.

In summary, the detection and management of ICI-associated cardiotoxic reactions are challenging, and more efforts are needed in future. First and foremost, one of the most important challenges is to improve preventive measures and increase early detection of cardiac toxicity *via* monitoring of cardiac damage. Second, a multidisciplinary team constituting of oncologists, cardiologists, radiologists, immunologists, and pathologists should be organized to achieve optimal management of ICI-induced cardiotoxicity and to decrease its lethal capacity. Further, developing cardiac protectants that can be used in conjunction with ICIs will be critical in preventing ICI cardiotoxicity. Last but not least, research into new immunotherapeutic agents with unknown cardiotoxicity incidence, such as anti-T cell Ig or anti-lymphocyte-activated gene-3 and mucin-containing protein 3, as well as V-domain Ig suppressor of T cell activation or B and T lymphocyte attenuator blockade, would be a new challenge for physicians. In addition, more clinical trials should focus on the effects of T cell costimulation blockers on cardiovascular disease. For example, CD40--TRAF6 inhibitors have already been well examined. Blocking OX40 and anti-4-1BB costimulation could be a promising strategy in the future ([@B111]).

Conclusion {#s7}
==========

Immune checkpoint inhibitors, either alone or in combination, can result in cardiotoxic adverse reactions, such as myocarditis, pericarditis, conduction abnormalities, cardiomyopathy, acute coronary syndrome, and others. Of all ICI-related cardiotoxic events, myocarditis is the most common cardiotoxic reaction. Though the incidence of ICI-associated cardiotoxicity remains relatively low, clinicians must be aware of these adverse events due to their high fatality rate. It mainly occurs in the early stage after ICI initiation, with nonspecific symptoms ranging from asymptomatic cardiac biomarker elevation, fatigue, and general malaise to chest pain, dyspnea, palpitations, multiorgan failure, cardiogenic shock, and cardiac arrest. A high level of clinical suspicion and early diagnosis indicators are required due to the rapid progress and fulminant course of the disease. The assessment of clinical features in combination with laboratory examinations (cTnI, cTnT, CK, CK-MB, BNP, and NT-proBNP), ECG, TTE, CMR, and EMB contribute to the diagnosis of ICI-associated cardiotoxicity. Among these diagnostic methods, troponin is generally the most sensitive marker, ECG has widespread availability and is easily performed, and EMB is a gold standard diagnosis. Before initiating ICIs, a comprehensive assessment of cardiovascular risk factors and a detailed cardiac history should be obtained, especially for patients with autoimmune disease or pre-existing cardiac disease, and when ICIs are combined with other treatments. For patients with confirmed cardiotoxic events, prompt high-dose steroids and other immunosuppressors, such as ATG, immunoglobulin, infliximab, tacrolimus, mycophenolate mofetil, rituximab, CTLA-4 agonists, and alemtuzumab can result in clinical recovery and increased survival. Auxiliary therapies, such as ACEIs, beta-blockers, aspirin, diuretics, antiarrhythmic drugs, pacemaker placement, and pericardiocentesis can also help. In addition, cardiac function assessment and frequent monitoring are necessary. To better understand the pathogenesis of this disease and provide effective treatment strategies, larger studies are needed.

Author Contributions {#s8}
====================

YZhou collected and reviewed the literature and wrote the manuscript. YZhu wrote and revised the manuscript. MW and YX rechecked the manuscript and put forward meaningful comments on it. CC, TZ, and FX assisted in drawing. JL and ZD contributed equally to writing the design and revised the manuscript. All authors read and approved the final manuscript.

Funding {#s9}
=======

This study was supported by the National Clinical Research Center for Geriatrics (West China Hospital, Z2018B12),1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (ZYJC18022), and Sichuan Science and Technology Department Key Research and Development Project (2019YFS0539).

Conflict of Interest {#s10}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[^1]: Edited by: Shuang Zhou, University of Houston, United States

[^2]: Reviewed by: Zhejian Ji, Harvard Medical School, United States; Feng Tian, Harvard Medical School, United States

[^3]: This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology
